By Phil Lassiter : The global medical device market reached $331 billion in 2012, a growth rate of 3% from 2011. According to a report from EvaluatePharma , the medical device market growth rate is expected to accelerate to 4.4% annually and reach $440 billion by 2018. That is a growth rate almost
By Futuristics: NuVasive ( NUVA ) recently announced its third-quarter ..... and a maturing spine market allowed NuVasive to beat analysts' third quarter revenue ..... sales force stability are boosting NuVasive 's stock price to gain further upside
Investment Research : NuVasive ( NUVA ) is $1.5 billion ..... body's nerve anatomy. NuVasive was founded in 1997 ..... in 2012. Last week, NUVA reported strong third ..... consensus of $0.13. NuVasive 's management raised
NuVasive ( NUVA ): Q1 EPS of $0.26 beats by $0.04 . Revenue of $159.5M (+5.2% Y/Y) beats by $2.06M . ( PR ) Post your comment!
treatment. Additionally, smaller competitors such as NuVasive NUVA have introduced new biologic products that compete with ..... be bundled with its hardware and instrument systems, NuVasive has been able to attract more spinal surgeons to embrace
By Kapitall : Value investors look for opportunities to buy stocks that are trading at significant discounts to their fair value, with the assumption that they’ll move up to their fair value in the near future. One proxy for fair value is analyst target price. We ran a screen on technically ...
We are no longer providing equity research on NuVasive NUVA . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
NuVasive NUVA announced its intentions to issue $325 ..... issue. In terms of valuation, we think NuVasive shares are about fairly valued, so we ..... a potential credit-sensitive play at NuVasive . We've seen 10-year issues of BBB
NuVasive NUVA reported fourth-quarter earnings that ..... commercial insurers still provide coverage for NuVasive 's lateral procedure though, after deeming ..... and long-term assumptions. We think NuVasive will have to largely generate growth in
We are placing NuVasive NUVA under review as we update our valuation. As we noted previously, we will moderately cut our fair value estimate due to a decrease